: Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis | wallstreet:online

Links shared publicly online about this topic.

  • 819
    total visits

: Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis | wallstreet:online

wallstreet-online.de —

NEW YORK, October 7, 2010 /PRNewswire/ - Results Presented at the Annual Meeting of the European Academy of Dermatology and Venereology in Gothenburg, Sweden Pfizer Inc. (NYSE: PFE) today announced that data from a Phase 2 efficacy and ...

View full resource at wallstreet-online.de

Tags: Dermatology, Psoriasis, Phase 2 Clinical Trial, Pfizer

  • Share

Most Recently Shared on October 7, 2010 at 4:05 pm By:

Dermatology_OW Dermatology Wisdom

Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moder... http://bit.ly/9xVZyZ

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

Oral Health OW Oral Health OW

Advertisement